modelGlycerol
Extends from Pharmacolibrary.Drugs.ATC.A.A06AX01.
Information
| name: | Glycerol | |
| ATC code: | A06AX01 | route: | oral |
| compartments: | 1 | |
| dosage: | 15000 | mg |
| volume of distribution: | 0.6 | L |
| clearance: | 0.07 | L/min |
| other parameters in model implementation | ||
Glycerol (glycerin) is a simple polyol compound used medically as an osmotic laxative and for reducing intracranial or intraocular pressure. It is also used in a variety of pharmaceutical formulations and as a food additive. Glycerol is approved for medical use and is broadly regarded as safe.
Pharmacokinetics
Estimated pharmacokinetic parameters for adult healthy individuals derived from published secondary sources, as no study reports explicit compartmental model PK parameters for glycerol in humans.
References
de Jonge, ME, et al., & Beijnen, JH (2005). Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL. British journal of clinical pharmacology 59(3) 325–334. DOI:10.1111/j.1365-2125.2004.02325.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/15752379
Liu, X, et al., & Leggas, M (2019). Pharmacokinetic modeling of the blood-stable camptothecin analog AR-67 in two different formulations. Biopharmaceutics & drug disposition 40(8) 265–275. DOI:10.1002/bdd.2199 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31292985
Gietka-Czernel, M, et al., & Zgliczyński, W (2020). Expert opinion on liquid L-thyroxine usage in hypothyroid patients and new liquid thyroxine formulation - Tirosint SOL [Opinia ekspertów dotycząca stosowania płynnej postaci lewotyroksyny oraz nowego preparatu Tirosint SOL u chorych na niedoczynność tarczycy]. Endokrynologia Polska 71(5) 441–465. DOI:10.5603/EP.a2020.0065 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33202031
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)